1. 157P Phase I expansion of IMC-C103C, a MAGE-A4×CD3 ImmTAC bispecific protein, in ovarian carcinoma. (December 2022) Authors: Sweis, R.; Garralda, E.; Saavedra Santa Gadea, O.; Moore, K.N.; Davar, D.; Hamid, O.; Segal, N.H.; Evans, T.R.J.; Dar, M.; Yuan, Y.; Collins, L.; Kirk, P.B.; Karakuzu, O.; Lopez, J.S.; Melero, I. Journal: Immuno-oncology technology Issue: Volume 16(2022)Supplement 1 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. 173P First-in-human study to evaluate the safety and clinical activity of FS222: A tetravalent bispecific antibody targeting PD-L1 and CD137, in patients with advanced solid tumors. (December 2022) Authors: De Velasco Oria, G.A.; Garralda, E.; Moreno Garcia, V.; Melero, I.; Victoria Ruiz, I.; Indacochea, A.; Cervantes, A.; Oberoi, A.; Jones, D.; Lakins, M.A.; Kayitalire, L. Journal: Immuno-oncology technology Issue: Volume 16(2022)Supplement 1 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. 175P Safety and preliminary efficacy of GEN1042 (DuoBody-CD40x4-1BB) combination therapy in patients with advanced solid tumors. (December 2022) Authors: Melero, I.; Grande Pulido, E.; De Miguel Luken, M.J.; Johnson, M.L.; Bauman, J.R.; Moreno Garcia, V.; Walter, A.O.; Adams, H.; Türeci, Ö.; Russo, G.; Sahin, U.; Steinberg, J.; Ahmadi, T.; Felip, E. Journal: Immuno-oncology technology Issue: Volume 16(2022)Supplement 1 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. 200MO Anti–IL-8 BMS-986253 + nivolumab (NIVO) ± ipilimumab (IPI) in patients (pts) with advanced cancer: Update of initial phase I results. (December 2022) Authors: Simonelli, M.; Calvo, E.; Davar, D.; Richards, D.; Gutierrez, M.; Moreno Garcia, V.; Marron, T.; Rottey, S.; Orcurto, A.; Renouf, D.J.; Joerger, M.; Barriga Falcon, S.; Fan, J.; Gibson, E.; Chakraborty, D.; Arora, V.; Melero, I. Journal: Immuno-oncology technology Issue: Volume 16(2022)Supplement 1 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
5. 219O Safety and preliminary efficacy of nivolumab in patients with advanced hepatocellular carcinoma: interim analysis of the phase 1/2 CheckMate-040 study. (20th December 2016) Authors: Melero, I.; Sangro, B.; Yau, T.; Hsu, C.; Kudo, M.; Crocenzi, T.; Kim, T-Y.; Choo, S.P.; Trojan, J.; Meyer, T.; Welling, T.H.; Yeo, W.; Chopra, A.; Anderson, J.; Dela Cruz, C.; Lang, L.; Neely, J.; El-Khoueiry, A. Journal: Annals of oncology Issue: Volume 27(2016:Sep.)Supplement 9 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
6. 505 Clinical evidence of intra-tumoral immune activation and tumor targeting with RG, a CEA-targeted engineered IL-2 immunocytokine. (September 2015) Authors: Tabernero, J.; Homicsko, K.; Schellens, J.H.; Hoekstra, O.; Van der Veen, L.; Melero, I.; és, G. Argil; Mau-Sorensen, M.; Angevin, E.; Joensuu, H.; Van Brummelen, E.; van Oordt, C.W. Menke-van der Houven; Nayak, T.; Romagnoli, S.; Reis, B.; Brossard, S. Soehrman; Evers, S.; Saro, J.; Verheul, H.;... Journal: European journal of cancer Issue: Volume 51:(2015)Supplement 3 Page Start: S104 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗